Bayer wins FDA breakthrough therapy designation for NSCLC candidate
Bayer’s oral tyrosine kinase inhibitor is currently in a Phase I trial estimated to enrol 460 patients.
Bayer’s oral tyrosine kinase inhibitor is currently in a Phase I trial estimated to enrol 460 patients.
What's Your Reaction?
